AIDS Progression Reduced by Almost Two-Thirds with Protease Inhibitor Crixivan, Brazil Trial Shows
MAR-21-1997 11:43 FROM MHHD PUBLIC AFFAIRS TO 916199424979 P.005/006 4. CRIXIVAN is the first drug to emerge from MSD's AIDS research program, which began in 1986 and led to breakthrough discoveries that became the basis for the development of protease inhibitors. MSD is a leading research-driven pharmaceutical products and services company. MSD discovers, develops, manufactures and markets a broad range of innovative pharmaceutical products to improve human health.
About this Item
- Title
- AIDS Progression Reduced by Almost Two-Thirds with Protease Inhibitor Crixivan, Brazil Trial Shows
- Author
- Merck Sharp & Dohme.
- Canvas
- Page 4
- Publication
- Merck Sharp & Dohme.
- 1997-03-21
- Subject terms
- press releases
- Series/Folder Title
- Disease Management > AIDS Vaccines > Clinical Trials > Trials of ACTG 320, Quattro, Brazil, Enalaprilat, and Efavirenz
- Item type:
- press releases
Technical Details
- Collection
- Jon Cohen AIDS Research Collection
- Link to this Item
-
https://name.umdl.umich.edu/5571095.0344.013
- Link to this scan
-
https://quod.lib.umich.edu/c/cohenaids/5571095.0344.013/4
Rights and Permissions
The University of Michigan Library provides access to these materials for educational and research purposes, with permission from their copyright holder(s). If you decide to use any of these materials, you are responsible for making your own legal assessment and securing any necessary permission.
Related Links
IIIF
- Manifest
-
https://quod.lib.umich.edu/cgi/t/text/api/manifest/cohenaids:5571095.0344.013
Cite this Item
- Full citation
-
"AIDS Progression Reduced by Almost Two-Thirds with Protease Inhibitor Crixivan, Brazil Trial Shows." In the digital collection Jon Cohen AIDS Research Collection. https://name.umdl.umich.edu/5571095.0344.013. University of Michigan Library Digital Collections. Accessed June 9, 2025.